PG LOGO 1200x628px.jpg
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)
December 04, 2023 07:00 ET | Polaris Group
TAIPEI, Taiwan and SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that...
Cellectis Logo.png
Monthly information on share capital and company voting rights
December 01, 2023 16:30 ET | Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 ...
MnM_logo_TM_JPG.JPG
Particle Size Analysis Market worth $596 million | MarketsandMarkets.
November 30, 2023 07:30 ET | MarketsandMarkets Research Pvt. Ltd.
Chicago, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Particle Size Analysis Market in terms of revenue was estimated to be worth $446 million in 2023 and is poised to reach $596 million by 2028, growing at a...
PG LOGO 1200x628px.jpg
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study
November 29, 2023 19:59 ET | Polaris Group
TAIPEI, Taiwan and SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the first patient was successfully dosed in the Phase 2a clinical study...
PR - Resizing - Kaplan Fox Tagline Logo Color.jpg
Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
November 28, 2023 13:44 ET | Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc. (Nasdaq: SLRN) common stock.
PG LOGO 1200x628px.jpg
Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma
November 16, 2023 19:49 ET | Polaris Group
TAIPEI, Taiwan and SAN DIGEO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the Company has initiated the rolling submission of its Biologic License...
Proxygen_Logo_RGB_500px.jpg
Proxygen Announces Formation of Scientific Advisory Board
November 15, 2023 07:00 ET | Proxygen
SAB Comprised of Pioneers in the Field of Protein Degradation, Including Unique Expertise in Roles of Ubiquitin Biology and Translational Medicine Track Records of Founding Biopharma Companies and...
Cellectis Logo.png
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
November 15, 2023 02:30 ET | Cellectis Inc.
Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023.Extraordinary shareholders’...
BioTech Breakthrough Awards Badge[1] copy.jpg
K36 Therapeutics Named “Overall BioPharma Startup of the Year” By BioTech Breakthrough
November 08, 2023 08:05 ET | BioTech Breakthrough
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- K36 Therapeutics (“K36”) has been selected as “Overall BioPharma Startup of the Year” in the third annual BioTech Breakthrough Awards Program...
BioTech Breakthrough Awards Badge[1] copy.jpg
BioTechnology Innovators Honored in 3rd Annual BioTech Breakthrough Awards Program
November 08, 2023 08:00 ET | BioTech Breakthrough
LOS ANGELES, Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology...